Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8616107 | 1.00 | MCL1 (0.60) | MCL1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL228292 | 0.94 | LMNA (0.67) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL4953 | 0.92 | LMNA (0.64) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL197017 | 0.90 | LMNA (0.72) | MCL1LMNACYP1A2PTGS1SLC6A2 | |
| Methyl Alcohol SCHEMBL27428217 | 0.89 | LMNA (0.66) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| Formaldehyde SCHEMBL27728539 | 0.89 | RXRA (0.62) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL12717358 | 0.89 | LMNA (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL23483029 | 0.88 | LMNA (0.69) | MCL1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL1096817 | 0.88 | LMNA (0.69) | MCL1LMNACYP1A2PTGS1SLC6A2 | |
| SCHEMBL378828 | 0.87 | GSTP1 (0.58) | MCL1LMNACYP1A2PTGS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072491-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20180142152-A1 | COMPOUNDS FOR THE HOMEOTROPIC ALIGNMENT OF LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| US-9761804-B2 | Oligomeric organic light emitting diode (OLED) materials containing multiple crosslinking functions | LOMOX LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9761804-B2 | Oligomeric organic light emitting diode (OLED) materials containing multiple crosslinking functions | LOMOX LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| EP-2697232-B1 | 6,7-DIHYDROIMIDAZO[2,1-B][1,3]OXAZINE BACTERICIDES | OTSUKA PHARMA CO LTD (JP) | 2016-05-18 | — | — | EP | disclosed |
| US-9051333-B2 | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20110118429-A1 | CHARGE TRANSPORT MATERIALS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-19 | — | — | US | disclosed |
| US-6388146-B1 | AROMATIC UNSATURATED NOMONER | SHARP KABUSHIKI KAISHA (JP) | 2002-05-14 | — | — | US | disclosed |
| US-5814378-A | ACRYLATED ESTER OF A BIPHENYL COMPOUND | SHARP KABUSHIKI KAISHA (JP) | 1998-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | MCL1 4011/4885LMNA 1218/4885CYP1A2 146/4885 |
| US-20140031342-A1 | 6,7-DIHYDROIMIDAZO [2,1-b] [1,3]OXAZINE BACTERICIDES | BRD1, OXA1L, QDPR | MCL1 3073/4885LMNA 4252/4885CYP1A2 594/4885 |
| US-20110118429-A1 | CHARGE TRANSPORT MATERIALS | SLC6A19, SLC6A15, SLC43A3 | MCL1 4707/4885LMNA 1190/4885CYP1A2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.